SCHEMBL4156930

SCHEMBL4156930

c1ccc(CNc2cnc3ccccc3n2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 2/20 0.64
PDGFRA P16234 2/20 0.64
KDM4E B2RXH2 4/20 0.60
ALDH1A1 P00352 3/20 0.60
POLB P06746 2/20 0.60
GAA P10253 1/20 0.60
PDE10A Q9Y233 1/20 0.58
HPGD P15428 2/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
FABP1 P07148 1/20 0.53
FABP6 P51161 1/20 0.53
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
RAD52 P43351 2/20 0.51
NOS2 P35228 1/20 0.50
PCSK9 Q8NBP7 1/20 0.48
LMNA P02545 1/20 0.48
CASP1 P29466 1/20 0.48
CASP7 P55210 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14129594 0.87 KDM4E (0.54) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL4640092 0.85 NPC1 (0.64) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL18171881 0.83 PDGFRB (0.61) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL780564 0.83 PDGFRB (0.61) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL30223599 0.83 KDM4E (0.66) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL18912907 0.83 KDM4E (0.66) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL14098736 0.82 MRGPRX4 (0.54) PDGFRBPDGFRAKDM4EALDH1A1POLB
SCHEMBL3908370 0.79 PDGFRB (1.00) PDGFRBPDGFRAKDM4EALDH1A1GAA
SCHEMBL3910327 0.78 PDGFRB (0.78) PDGFRBPDGFRAKDM4EALDH1A1HPGD
SCHEMBL29558717 0.77 ALDH1A1 (0.56) PDGFRBPDGFRAKDM4EALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115747838-A Method for synthesizing amino-substituted quinoxalinone compound through electrochemical reaction 南京师范大学 2023-03-07 CN disclosed
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2009-07-23 US disclosed
CN-101300236-A Triazole compounds as lipoxygenase inhibitors BIOLIPOX AB (SE) 2008-11-05 CN disclosed
EP-1943234-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS Biolipox AB (SE) 2008-07-16 EP disclosed
WO-2007051982-A1 TRIAZOLE COMPOUNDS AS LIPOXYGENASE INHIBITORS BIOLIPOX AB (SE) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186918-A1 Triazole Compounds as Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 PDGFRB 2362/4885PDGFRA 2938/4885KDM4E 3030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.